© 2020 MJH Life Sciences and Urology Times. All rights reserved.
July 23, 2020
Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.
Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.
The study compared the 2 procedures over 24 months of follow-up.
July 22, 2020
Retreatment rates were low with both aquablation and transurethral resection of the prostate.
Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.
July 21, 2020
In patients with prior exposure to PDE5 inhibitors, increasing the number of sessions of low-intensity shockwave therapy was associated with improving outcomes.
The EUPROMS patient-driven quality-of-life study included data from almost 3000 men treated for prostate cancer.
July 20, 2020
Steroid sulfatase inhibition showed early activity as a precision option in castrate-resistant prostate cancer, including the potential to enhance response to enzalutamide.